Rigel Pharmaceuticals (NASDAQ:RIGL)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 1.31. At the close of trading, the stock’s price was $20.13, to imply an increase of 16.02% or $2.78 in intraday trading. The RIGL share’s 52-week high remains $29.82, putting it -48.14% down since that peak but still an impressive 62.84% since price per share fell to its 52-week low of $7.48. The company has a valuation of $354.59M, with an average of 0.22 million shares in intraday trading volume over the past 10 days and average of 259.69K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Rigel Pharmaceuticals (RIGL), translating to a mean rating of 2.33. Of 5 analyst(s) looking at the stock, 0 analyst(s) give RIGL a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.48.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
After registering a 16.02% upside in the last session, Rigel Pharmaceuticals (RIGL) has traded red over the past five days. The 5-day price performance for the stock is 23.88%, and 5.17% over 30 days. With these gigs, the year-to-date price performance is 19.68%. Short interest in Rigel Pharmaceuticals (NASDAQ:RIGL) saw shorts transact 0.81 million shares and set a 2.55 days time to cover.
The extremes give us $1 and $2 for target low and target high price respectively. As such, RIGL has been trading 90.06% off suggested target high and 95.03% from its likely low.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
Looking at statistics comparing Rigel Pharmaceuticals share performance against respective industry, we note that the company has outperformed competitors. Rigel Pharmaceuticals (RIGL) shares are 109.25% up over the last 6 months, with its year-to-date growth rate higher than industry average at 115.71% against 16.60%. The rating firms project that company’s revenue will grow 53.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 57.59M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 44.69M.Earnings reports from the last fiscal year show that sales brought in 35.79M and 29.53M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 60.89% before jumping 51.33% in the following quarter.
RIGL Dividends
Rigel Pharmaceuticals has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders
Rigel Pharmaceuticals insiders hold 2.18% of total outstanding shares, with institutional holders owning 67.95% of the shares at 69.46% float percentage. In total, 67.95% institutions holds shares in the company, led by BARCLAYS PLC. As of 2024-06-30, the company held over 10573.0 shares (or 0.006% of shares), all amounting to roughly $88000.0.
The next major institution holding the largest number of shares is IFP ADVISORS, INC with 1000.0 shares, or about 0.0006% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $807.0.
We also have Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Rigel Pharmaceuticals (RIGL) shares. Going by data provided on Oct 31, 2024 , Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF holds roughly 1.05 shares. This is just over 5.98% of the total shares, with a market valuation of $21.22 million. Data from the same date shows that the other fund manager holds a little less at 548.78, or 3.12% of the shares, all valued at about 11.05 million.
